AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1
Conclusions
- HER3 and MUC1 are co-expressed in a variety of solid tumors, especially those with the highest mortality.
- DM002 is a novel fully human bispecific antibody-drug conjugate generated by the RenLite® common light chain mouse platform. DM002 cross-reacts with human and monkey HER3 and the MUC1 juxtamembrane domain.
- DM002 displayed higher endocytosis activity and more potent tumor growth inhibition of HER3 and MUC1 co-expressing tumors (especially HER3low tumors) compared to HER3 and MUC-1 benchmarks.
- DM002 is a promising First-In-Class ADC with potential to treat a variety of HER3 and MUC-1-expressing cancers.
